BrightSpring Health Services announced on November 6, 2024, that its subsidiary, CareMed, a leading independent Specialty Pharmacy, has been selected by Eisai as the national specialty pharmacy provider for Leqembi®. Leqembi is a cutting-edge treatment specifically designed for Alzheimer’s disease, targeting aggregated soluble and insoluble forms of amyloid beta.
The FDA approval of Leqembi is based on the results of a Phase III clinical trial, which demonstrated that patients with mild cognitive impairment or mild dementia stage of Alzheimer’s disease who received Leqembi showed a slowed progression of cognitive impairment over an 18-month period compared to those on placebo. This partnership positions CareMed at the forefront of distributing a significant new therapy.
This collaboration highlights CareMed's commitment to increasing patient access to innovative medications and treatments for devastating diseases like Alzheimer's. BrightSpring's President and CEO, Jon Rousseau, emphasized the importance of bringing more treatment options to patients and delivering comprehensive support and care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.